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A group of orthodontists plan to run a clinical trial to compare the alignment duration using three different 
kinds of fixed appliances. Group A will receive conventional 0.0186 x 0.025-inch straight-wire appliances 
with a standard archwire sequence ligated with conventional elastomeric ligatures. Group B will receive the 
same fixed appliance plus the application of low level laser therapy at every appointment. Group C will the 
receive the same fixed appliance as Group A plus the application of corticotomies at every appointment. 
The trial’s primary endpoint is to be the duration of the alignment phase of fixed appliance treatment, which 
will be calculated as the sum of days needed from appliance insertion until a rectangular 0.0166 x 0.022-
inch stainless steel archwire can be passively inserted in the slots of all brackets. 
The authors want their trial to be adequately-powered to provide a definitive answer to the research 
null hypothesis that there is no difference in the alignment duration among the three appliance groups 
evaluated. Therefore, they conduct an a priori sample size calculation, using as reference a previous trial 
(Ong et al., 2011), which they judge to be set similarly to their own. The expected value for Group A is taken 
from that reference trial to be 132.0 days (standard deviation of 36.0 days) and they hypothesize a 10% 
reduction (118.8 days) and a 20% reduction (105.6 days) in the alignment duration of Groups B and C, 
respectively (with a common standard deviation of 36.0 days). They aim to use a one-way analysis of 
variance to analyse the data and set the significance level (type I error rate) at 5%, while aiming for power 
of 90% (i.e. 1 minus a 10% type II error rate). This sample size calculation indicates that 49 patients/group 
would be needed (147 patients in total), which is increased to a recruitment goal of 57 patients/group (171 
patients in total) to account for an expected 15% drop-out rate. 
The clinical trial is initiated according to its registered protocol and a total of 171 patients are 
allocated with a 1:1:1 allocation ratio in the three groups (57 patients/group). After administering the planned 
interventions, the patients are followed up until trial completion when the same stainless steel working 
archwire is placed passively in all patients. At this point outcome data is collected from 150 patients in total, 
as several patients dropped out of the trial and no outcome data was available. The reasons for these 26 
missing patients were: discontinuation due to poor oral hygiene or poor compliance (6 patients), relocation 
(5 patients), pain or discomfort (15 patients). 
The authors analyse the data and find no statistically significant difference in the alignment duration 
among the three groups, concluding that their trial provided robust evidence about the similar clinical 
performance of the three groups.  
 
Which of the following statements are correct, if any: 
(A) The current trial is adequately powered to identify the hypothesised difference in alignment duration, 
since a sample size calculation was performed. 
(B) The current trial might be adequately powered to identify the hypothesized difference in alignment 
duration, since a sample size calculation was performed, and drop-outs were less than the expected 15% 
(26 drop-outs / 171 patients ~ 15%). 
(C) Estimations about the alignment duration in each of the three groups of the trial can be done with similar 
precision, since patients in the trial were randomized with a 1:1:1 allocation ratio. 
(D) The fact that the drop-outs were not similar across the three groups introduces de facto bias in the trial’s 
results. 
(E) The uneven drop-out rate across the three groups might introduce bias in the trial’s results, if the reasons 
for the drop-outs are related to the administered intervention. 
 
Discussion 
The subject of a trial’s statistical power and how it relates to sample size calculation has been somewhat 
discussed in previous issues (Papageorgiou 2019a,b). The current trial included a sample size calculation 
aiming to identify a 10%-20% reduction in alignment duration with 90% power, which indicated that at least 
49 patients/group (147 in total) would be needed to be analysed. Therefore, if the hypothesised difference 
in alignment duration (10%-20%) or one larger than that exists in reality, then the current trial would have 
adequate power (here, interpreted as 90% power) to identify this. This, of course, holds true only on the 
condition that the originally planned sample of 49 patients/group (147 in total) are included and finally 
analysed at the trial’s conclusion. So statement (A) does not necessarily hold true and performing an a priori 
sample size calculation is a necessary, but not adequate, step in ensuring a trial is adequately powered.  
It is however generally accepted that in most clinical trials are prone to some loss of participants 
and therefore data that can be eventually analysed. These patient “drop-outs” can occur in different phases 
of a clinical trial and be of variable magnitude – especially in clinical trials with prolonged follow-up durations 
of many years. For example, a patient that has been randomised to one group might fail to attend the next 
appointment, where treatment will be administered. Similarly, a patient might not be available for any of the 
following appointments, where treatment is continued or the patient is simply observed. Usually though, 
drop-out rates of 10%-20% are considered moderate and might not necessarily be an issue to the trial’s 
credibility, provided they do not overly reduce the sample being available for analysis. This is also the reason 
why many trialists take into account during the planning stage of the protocol the expected patient drop-outs 
in their sample size calculation. Simply put, the required sample to be recruited is inflated by the expected 
drop-out rate so that the sample after drop-outs still that is finally analysed has adequate statistical power. 
In the current theoretical example the overall drop-out rate was in the average magnitude that was expected 
and incorporated (15%) and we might reasonably assume that the trial might have adequate statistical 
power to identify the target effect size (if this really exists). This supports statement (B). 
Patient drop-outs during a trial are generally to be expected in clinical research and might not be 
detrimental to a trial’s credibility – provided they are of small to moderate and occur at random. The occurring 
at random can be interpreted as (i) drop-outs being of the same magnitude more across all randomised 
groups, (ii) drop-outs occurring at the similar phases of treatment, and (iii) lack of any systematic pattern 
that dictates patient drop-outs. Points (i) and (ii) are of particular interest, since drop-outs decrease the 
analysed sample in each group and through this the statistical analysis. Looking at the theoretical example 
of this trial we can see that Group A and Group B have a larger number of analysed patients that Group C 
(51 patients compared to 43 patients), which contradicts the 1:1:1 initial allocation ratio. This in turns means 
that we run the risk of observing larger standard deviations in Group C than the other two groups, which 
might not be related to a more heterogeneous clinical treatment response, but might be due to sampling 
reasons. Consequently, this might translate to greater imprecision in the effect estimation compared to the 
other two groups that might not enable us to identify an existing difference. Therefore, statement C is not 
true. 
Finally, when interpreting the results of a clinical trial, it is very important to know and critically 
appraise the reasons for any observed drop-outs in order to ascertain that no systemic pattern exists. 
Several reasons might exist for an initially randomised patient not being analysed in the end. The reasons 
for a patient missing on a planned appointment might be for personal reasons that have little to do with the 
treatment, like the patient moving to a different location, the patient being ill, or just not motivated enough. 
Similarly, trial outcome data might be missing randomly in the end due to the dental casts or radiographs 
being lost or of low quality. These drop-outs cannot be predicted by a single factor and are thought to be 
missing at random and not introduce bias in the trial’s results (so statement D is false). On the other side, 
patients might be prone to miss an oncoming appointment or discontinue treatment completely if the 
administered treatment (i) does not work as expected and/or (ii) is associated with adverse effects to the 
patient. In this case it might be possible that reduced efficacy or disproportionate harms have influenced the 
comparability of the analysed sample, which introduces bias in the trial’s results since the sample doesn’t 
any more represent the average recruited patient. In the present theoretical example, the trialists 
meticulously noted and reported the reasons for patient drop-outs in Table 1. 
 
Table 1. Patient drop-outs during the trial with details. 
Status Total Group A Group B Group C 
Recruited 171 57 57 57 
     
Drop-outs: poor hygiene / compliance 6 3 2 1 
Drop-outs: relocated 5 2 2 1 
Drop-outs: pain / discomfort 15 1 2 12 
Drop-outs (total) 26 6 6 14 
     
Analysed 145 51 51 43 
 
 
It is immediately obvious that drop-outs due to poor oral hygiene / compliance and relocations are relatively 
similar across the three groups. On the otherside, the vast majority (80%) of drop-outs due to patient-
reported adverse effects (pain / discomfort) are found in Group C. If one also considers that Group C 
received the most invasive surgical procedure of the three groups, it might be reasonably to assume that 
the administered corticotomies could have been followed by adverse effects like bleeding, inflammation, 
pain, etc. This is important information that must be meticulously reported in the trial’s report according to 
the CONSORT (Consolidated Standards of Reporting Trials) statement (Moher et al., 2010) in order to be 
able to fairly appraise the clinical performance of an intervention, but is often under-reported (Harrison 
2003). Apart from that however, excluding patient drop-outs from the analysis might introduce bias in the 
trial’s results, since a particular part of the original sample is missing and the groups are not comparable 
anymore. Therefore, statement (E) is true. In such cases, advanced statistical methods (Unnebrink and 
Windeler, 2001) might be needed in order to impute the missing patients and reduce the risk of bias. 
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